maklogo
Market Research Report

Global POC Hematology Diagnostic Market Insights, Size, and Forecast By Application (Complete Blood Count, Blood Typing, Coagulation Testing), By End Use (Hospitals, Diagnostic Laboratories, Home Care Settings), By Technology (Microfluidics, Immunoassays, Nucleic Acid Testing), By Product Type (Portable Analyzers, Handheld Devices, Prefilled Test Kits), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035

Report ID:78036
Published Date:Jan 2026
No. of Pages:214
Base Year for Estimate:2025
Format:
Customize Report

Key Market Insights

Global POC Hematology Diagnostic Market is projected to grow from USD 2.8 Billion in 2025 to USD 5.9 Billion by 2035, reflecting a compound annual growth rate of 8.7% from 2026 through 2035. This market encompasses the point of care diagnostic solutions used for analyzing various hematological parameters directly at or near the patient, rather than requiring samples to be sent to a central laboratory. The primary drivers for this significant growth include the increasing prevalence of hematological disorders such as anemia, leukemia, and thrombocytopenia, demanding rapid and accessible diagnostic tools. Furthermore, the rising geriatric population, more susceptible to these conditions, fuels demand. Technological advancements leading to more accurate, portable, and user friendly devices are also critical contributors. The convenience and speed offered by POC hematology diagnostics, reducing turnaround times and enabling quicker clinical decisions, are becoming increasingly attractive to healthcare providers and patients alike. The market is also benefiting from a growing emphasis on early disease detection and personalized medicine, where rapid diagnostic insights can significantly impact treatment outcomes.

Global POC Hematology Diagnostic Market Value (USD Billion) Analysis, 2025-2035

maklogo
8.7%
CAGR from
2025 - 2035
Source:
www.makdatainsights.com

Key market trends include the miniaturization of diagnostic devices, integration with digital health platforms for seamless data management, and the development of multiplex assays capable of analyzing multiple parameters simultaneously from a single sample. There is also a notable shift towards non invasive or minimally invasive testing methods to enhance patient comfort and compliance. However, the market faces certain restraints, including the high initial cost of advanced POC devices, which can be a barrier for smaller clinics or healthcare systems in developing regions. Regulatory hurdles and the need for stringent quality control measures to ensure accuracy and reliability of results also pose challenges. Despite these, significant opportunities exist in expanding market penetration in underserved rural areas and emerging economies, where access to central laboratories is limited. The development of AI powered diagnostic algorithms for enhanced accuracy and the integration of telehealth services for remote monitoring and consultation further present lucrative avenues for growth. The leading segment within this market is Complete Blood Count, owing to its fundamental role as a primary diagnostic tool for a wide range of conditions and its widespread adoption in various clinical settings.

North America stands as the dominant region in the global POC Hematology Diagnostic Market. This dominance is attributed to well established healthcare infrastructure, high adoption rates of advanced medical technologies, significant research and development investments, and favorable reimbursement policies. The presence of major market players and a high awareness among both healthcare professionals and patients regarding the benefits of rapid diagnostics further solidify its leading position. Conversely, Asia Pacific is emerging as the fastest growing region. This rapid expansion is driven by improving healthcare infrastructure, increasing healthcare expenditure, a large patient pool, and growing awareness of early disease detection. The rising prevalence of chronic diseases and the expanding elderly population in countries within this region are also key factors contributing to its accelerated growth. Key players like A. Menarini Diagnostics, Siemens Healthineers, and Sysmex Corporation are employing strategies focused on product innovation, strategic partnerships, and expanding their geographical footprint to capitalize on the growing demand for accurate and rapid POC hematology diagnostic solutions globally. Other notable players such as Ortho Clinical Diagnostics and Roche Holding are actively investing in R&D to introduce novel technologies and enhance their product portfolios to maintain competitive advantages.

Quick Stats

  • Market Size (2025):

    USD 2.8 Billion

  • Projected Market Size (2035):

    USD 5.9 Billion

  • Leading Segment:

    Complete Blood Count (45.8% Share)

  • Dominant Region (2025):

    North America (38.2% Share)

  • CAGR (2026-2035):

    8.7%

What is POC Hematology Diagnostic?

POC Hematology Diagnostic refers to point of care testing in hematology, delivering rapid blood analysis at the patient’s side rather than in a central laboratory. These portable devices measure various blood parameters, including complete blood counts, coagulation markers, and specific cell types. The core concept emphasizes immediate results, facilitating quicker clinical decision making, improved patient management, and enhanced accessibility in diverse healthcare settings. Significance lies in their ability to accelerate diagnosis of conditions like anemia, infection, or clotting disorders, particularly valuable in emergency rooms, critical care units, remote clinics, or resource constrained environments, leading to more timely and effective interventions.

What are the Trends in Global POC Hematology Diagnostic Market

  • Microfluidic Innovations Driving Next Gen POC Hematology

  • AI ML Empowered Point of Care Blood Analysis

  • Telehealth Integration for Remote Hematology Diagnostics

  • Sustainable Solutions for POC Hematology Waste Reduction

Microfluidic Innovations Driving Next Gen POC Hematology

Microfluidic advancements are revolutionizing point of care hematology. Smaller sample volumes, faster results, and multiplexing capabilities are driving next generation devices. These innovations enable comprehensive blood cell analysis at the patient bedside, enhancing diagnostic speed, accuracy, and accessibility. This trend is accelerating decentralized, rapid, and precise hematological assessments, improving patient management globally.

AI ML Empowered Point of Care Blood Analysis

AI and ML transform point of care blood analysis by enhancing diagnostic accuracy, speed, and automation. These technologies enable rapid, reliable insights from small blood samples, improving patient outcomes. They streamline workflows, reduce manual errors, and provide predictive capabilities for better health management at the point of care, making diagnostics more accessible and efficient globally.

Telehealth Integration for Remote Hematology Diagnostics

Telehealth integration is revolutionizing remote hematology diagnostics within the global point of care market. This trend enables convenient virtual consultations and remote monitoring for patients, significantly improving accessibility to blood disorder management. By leveraging portable diagnostic tools, specialists can offer timely and accurate assessments regardless of location, optimizing patient care and reducing travel burdens. This innovation enhances diagnostic efficiency and patient satisfaction.

Sustainable Solutions for POC Hematology Waste Reduction

Sustainable solutions address the disproportionate environmental burden on communities of color from medical waste. This trend within global point of care hematology focuses on developing culturally competent and accessible waste reduction strategies. It aims to minimize disposable product usage, optimize recycling, and explore reusable alternatives for diagnostic tests performed on individuals from marginalized racial and ethnic groups, promoting health equity and ecological responsibility.

What are the Key Drivers Shaping the Global POC Hematology Diagnostic Market

  • Rising Demand for Rapid Diagnostics and Decentralized Testing

  • Technological Advancements and Miniaturization of Devices

  • Increasing Prevalence of Hematologic Disorders and Chronic Diseases

  • Expansion of Point-of-Care Settings and Untapped Geographies

Rising Demand for Rapid Diagnostics and Decentralized Testing

Increasing prevalence of chronic and infectious diseases drives demand for immediate diagnostic results. This fuels the adoption of point of care hematology solutions, enabling quicker diagnoses and treatment initiation at various healthcare settings. The shift towards decentralized testing, including home based and near patient options, further accelerates market growth by improving accessibility and convenience for patients.

Technological Advancements and Miniaturization of Devices

Progress in technology and shrinking device sizes are profoundly impacting POC hematology. Smaller, more powerful diagnostic tools are emerging, allowing sophisticated blood analysis closer to patients. This miniaturization enhances portability and accessibility, enabling rapid diagnosis in diverse settings from clinics to remote locations. These advancements drive greater adoption and expansion of POC hematology solutions globally.

Increasing Prevalence of Hematologic Disorders and Chronic Diseases

Rising instances of blood cancers like leukemia and lymphoma, along with common chronic conditions such as diabetes and cardiovascular disease, are fueling demand. These disorders often require frequent blood monitoring, driving the adoption of rapid, accessible point of care hematology diagnostics. Early and convenient testing aids in timely diagnosis and disease management for these growing patient populations.

Expansion of Point-of-Care Settings and Untapped Geographies

This driver emphasizes the growing demand for rapid hematology testing outside central laboratories. It highlights the increasing adoption of POC solutions in clinics, emergency rooms, and remote locations. Expanding into previously underserved or geographically isolated areas further fuels market growth, making testing more accessible and convenient for patients and healthcare providers.

Global POC Hematology Diagnostic Market Restraints

Lack of Reimbursement and Regulatory Challenges

Inadequate reimbursement for point of care hematology tests hinders adoption, as laboratories struggle to cover costs. Complex and varying regulatory landscapes across different regions further complicate market entry and product development. These financial and regulatory hurdles make it challenging for manufacturers to justify investment and for healthcare providers to offer these valuable diagnostic tools, particularly in price sensitive environments.

High Cost of POC Devices and Limited Test Menus

High costs of point of care hematology devices and their associated consumables hinder widespread adoption. Additionally, many current devices offer limited test menus compared to laboratory analyzers. This restricts the comprehensive diagnostic capabilities available at the point of care, requiring supplemental laboratory testing for a complete blood count or specific disease markers. These factors collectively deter healthcare providers from fully embracing POC hematology solutions, impacting market growth.

Global POC Hematology Diagnostic Market Opportunities

Unlocking Growth in Decentralized and Non-Traditional Care Settings via POC Hematology

This opportunity involves leveraging point of care hematology to deliver rapid, on site blood diagnostics in decentralized and non traditional settings. It unlocks significant growth by improving access to essential testing in clinics, community centers, and patient homes. This is vital for regions needing accessible healthcare, enabling earlier disease detection and more timely treatment. Expanding diagnostics beyond central labs caters to convenience demands, drives market penetration, and addresses unmet needs in underserved populations, ultimately enhancing patient care pathways.

Accelerating Clinical Decisions and Patient Outcomes with Rapid POC Hematology Diagnostics

Rapid point of care hematology diagnostics offer a significant global opportunity, particularly in fast-growing regions like Asia Pacific. These on-site blood tests deliver immediate results, empowering clinicians to make faster, more informed treatment decisions. This direct access to vital hematological data drastically reduces diagnostic turnaround times. Consequently, interventions are quicker, patient management improves, and health outcomes are enhanced. This innovation meets the urgent demand for efficient, accessible diagnostics, transforming patient care worldwide.

Global POC Hematology Diagnostic Market Segmentation Analysis

Key Market Segments

By Product Type

  • •Portable Analyzers
  • •Handheld Devices
  • •Prefilled Test Kits

By Application

  • •Complete Blood Count
  • •Blood Typing
  • •Coagulation Testing

By End Use

  • •Hospitals
  • •Diagnostic Laboratories
  • •Home Care Settings

By Technology

  • •Microfluidics
  • •Immunoassays
  • •Nucleic Acid Testing

Segment Share By Product Type

Share, By Product Type, 2025 (%)

  • Portable Analyzers
  • Handheld Devices
  • Prefilled Test Kits
maklogo
$2.8BGlobal Market Size, 2025
Source:
www.makdatainsights.com

Why is Complete Blood Count the leading segment in the Global POC Hematology Diagnostic Market?

Complete Blood Count stands as the dominant application primarily due to its indispensable role as a first line diagnostic tool across a vast spectrum of medical conditions. From identifying infections and anemia to screening for various inflammatory and blood disorders, CBC tests provide crucial insights into a patient's overall health. The growing emphasis on early diagnosis and rapid clinical decision making, especially in critical care and emergency settings, fuels the high demand for fast and reliable POC CBC results, making it foundational for patient management.

How do Product Type and End Use segments collectively drive accessibility in the POC Hematology Diagnostic Market?

The synergy between Product Type, specifically Handheld Devices and Portable Analyzers, and the End Use segment, particularly Home Care Settings and Diagnostic Laboratories, significantly enhances market accessibility. Handheld and portable solutions allow for testing outside traditional laboratory environments, bringing diagnostics closer to the patient. This is crucial for managing chronic conditions at home, facilitating immediate results in clinics, and supporting outreach programs, thereby expanding diagnostic reach and enabling decentralized healthcare delivery.

What role do advancing technologies play in shaping the future of POC Hematology Diagnostics?

Technological advancements, particularly in Microfluidics and Immunoassays, are pivotal in driving innovation within the POC Hematology Diagnostic Market. Microfluidics enables smaller, more efficient devices with reduced sample volumes and faster analysis times, improving user convenience and expanding the range of tests available at the point of care. Immunoassays are critical for specific applications like blood typing and detecting markers for coagulation disorders, offering high sensitivity and specificity. These technologies are crucial for developing next generation, multi parameter POC devices that enhance diagnostic capabilities and efficiency.

What Regulatory and Policy Factors Shape the Global POC Hematology Diagnostic Market

The global POC hematology diagnostics market navigates a complex patchwork of regional regulations. The US mandates FDA clearance, with CLIA waivers critical for broader point of care adoption. Europe adheres to the stringent In Vitro Diagnostic Regulation (IVDR) for CE marking, emphasizing clinical performance and post market surveillance. Asia Pacific regions like China (NMPA) and Japan (PMDA) maintain distinct national approval processes. All manufacturers must meet international quality management standards such as ISO 13485. Data privacy rules, like GDPR and HIPAA, impose additional compliance burdens for connected devices. Varying reimbursement policies significantly influence market access. These diverse, non-harmonized regulatory frameworks necessitate region-specific strategies, creating barriers to rapid global deployment.

What New Technologies are Shaping Global POC Hematology Diagnostic Market?

Innovations are rapidly transforming global POC hematology diagnostics, driving significant market expansion. Emerging technologies like advanced microfluidics enable highly miniaturized, lab quality analyzers for rapid blood count, coagulation, and even differential analysis at the point of care. Artificial intelligence and machine learning are enhancing result interpretation and quality control, ensuring greater accuracy and reducing human error. Connectivity features, including cloud integration and telehealth platforms, allow seamless data sharing and remote monitoring, crucial for decentralized testing and timely clinical decisions. Novel biosensors and cartridge based systems simplify operation, expanding accessibility in diverse healthcare settings. These advancements promise faster diagnostics, improved patient management, and better outcomes worldwide.

Global POC Hematology Diagnostic Market Regional Analysis

Global POC Hematology Diagnostic Market

Trends, by Region

Largest Market
Fastest Growing Market
maklogo
38.2%

North America Market
Revenue Share, 2025

Source:
www.makdatainsights.com

North America dominates the Global POC Hematology Diagnostic Market with a 38.2% share. The region's lead is attributed to advanced healthcare infrastructure, high adoption rates of innovative diagnostic technologies, and the strong presence of key market players. Additionally, increasing prevalence of chronic diseases and a growing elderly population further fuel demand for rapid and accurate hematology testing. Favorable reimbursement policies and significant investments in R&D also contribute to the region's prominent position, ensuring continued growth and technological advancements in POC hematology diagnostics.

Europe presents a mature but evolving regional market for POC hematology diagnostics. Western European countries demonstrate high adoption rates, driven by well-established healthcare infrastructure and a focus on decentralised testing for efficiency. Germany, UK, and France are key contributors, with strong demand from emergency rooms, critical care, and primary care settings. Eastern Europe, while growing, has slower adoption due to varying healthcare budgets and less established POC testing pathways. The region as a whole benefits from technological advancements, an aging population, and the need for rapid diagnostic turnaround. Regulatory landscapes and reimbursement policies significantly influence market dynamics across different European nations.

Asia Pacific dominates the POC hematology diagnostic market with an impressive 11.2% CAGR, making it the fastest-growing region. This surge is fueled by increasing prevalence of blood disorders, a growing geriatric population, and rising awareness regarding early diagnosis. Developed economies like Japan and Australia are experiencing rapid adoption due to advanced healthcare infrastructure and technological advancements. Meanwhile, emerging economies such as China and India are witnessing significant growth attributed to increasing disposable incomes, improving healthcare access, and a rise in point-of-care testing initiatives, particularly in rural areas. The region also benefits from a robust medical device manufacturing sector.

Latin America presents a dynamic landscape in the POC Hematology Diagnostic Market. Brazil and Mexico lead the region, driven by increasing healthcare expenditure, a rising prevalence of non-communicable diseases, and the growing demand for rapid diagnostic solutions in both hospital and private lab settings. However, challenges like budget constraints in public healthcare and the need for greater awareness of advanced diagnostics in remote areas persist. Point-of-care solutions are gaining traction due to their ability to improve patient outcomes in underserved regions. Companies are focusing on expanding distribution networks and offering cost-effective, easy-to-use devices to capture market share across diverse economic segments within the region.

The Middle East & Africa (MEA) POC hematology diagnostic market is experiencing steady growth, driven by increasing healthcare expenditure and the rising burden of hematological disorders. Gulf Cooperation Council (GCC) countries lead in adoption due to robust healthcare infrastructure and high disposable incomes. South Africa also presents a significant market, fueled by a high prevalence of anemia and HIV/AIDS, necessitating rapid diagnostic solutions. However, affordability and limited access to advanced technologies remain challenges in lower-income African regions. Strategic partnerships and localized manufacturing are crucial for market penetration, with a strong focus on cost-effective, portable devices suitable for remote settings and point-of-care testing.

Top Countries Overview

The United States dominates the global point of care hematology diagnostics market. Growing demand for rapid testing and technological advancements fuel this expansion. Key players are investing in research and development to introduce innovative and user friendly devices. This market exhibits strong growth potential.

China is a key player in the global point of care hematology diagnostics market. Its large population and increasing healthcare demands drive market growth. Local manufacturers compete with international companies, focusing on affordable and accessible diagnostic solutions. Technology advancements and government support further boost the market expansion.

India significantly contributes to the global point of care hematology diagnostics market. The nation shows increasing adoption of rapid, accessible diagnostic solutions, driven by rising chronic disease prevalence and expanding healthcare infrastructure. This growth is fueled by both domestic innovation and international collaborations.

Impact of Geopolitical and Macroeconomic Factors

Rising geopolitical tensions in Asia Pacific could disrupt supply chains for essential reagents and devices, impacting market availability and potentially increasing production costs. Healthcare budget reallocations due to economic downturns or pandemic responses may shift priorities away from new POC hematology diagnostics adoption, particularly in developing nations.

Inflationary pressures and interest rate hikes could constrain capital expenditure for laboratories, affecting their ability to invest in advanced POC systems. Government regulations regarding medical device approval and reimbursement policies will significantly influence market access and adoption rates globally.

Recent Developments

  • March 2025

    Siemens Healthineers announced a strategic partnership with Hematologic Technologies to integrate advanced AI-driven hematology analysis into their point-of-care diagnostics portfolio. This collaboration aims to enhance diagnostic accuracy and speed for a broader range of hematological disorders at the patient's side.

  • January 2025

    PathogenDx launched its new rapid POC hematology panel specifically designed for early detection of sepsis-related blood count changes. This innovative test provides comprehensive results within minutes, enabling faster clinical decisions and improved patient outcomes in critical care settings.

  • February 2025

    Sysmex Corporation acquired Mediwise, a leader in portable blood cell counter technology, to expand its presence in the handheld POC hematology market. This acquisition strengthens Sysmex's portfolio with highly mobile and user-friendly devices, catering to remote and decentralized healthcare settings.

  • April 2025

    Acon Laboratories initiated a large-scale clinical trial for its next-generation multi-parameter POC hematology analyzer across several developing countries. This strategic initiative focuses on validating the device's performance and cost-effectiveness for widespread adoption in resource-limited environments.

  • May 2025

    Ortho Clinical Diagnostics unveiled a new compact POC hematology system featuring microfluidic technology for efficient sample processing and analysis. This system is designed to provide hospital-grade accuracy in a much smaller footprint, making it ideal for physician offices and urgent care centers.

Key Players Analysis

Key players in the Global POC Hematology Diagnostic Market include Siemens Healthineers and Sysmex Corporation, leading with advanced automated hematology analyzers and informatics solutions driving market growth through efficiency and accuracy. Roche Holding, Acon Laboratories, and Ortho Clinical Diagnostics are also significant, focusing on developing rapid, point of care testing devices and next generation assays. Companies like Menarini Diagnostics and Greiner BioOne contribute with specialized reagents and consumables. Strategic initiatives across these players involve AI integration for enhanced diagnostics, expansion into emerging markets, and strategic partnerships, all fueled by increasing demand for decentralized testing and improved patient outcomes.

List of Key Companies:

  1. A. Menarini Diagnostics
  2. PathogenDx
  3. Siemens Healthineers
  4. Sysmex Corporation
  5. Ortho Clinical Diagnostics
  6. Acon Laboratories
  7. Greiner BioOne
  8. Roche Holding
  9. Hematologic Technologies
  10. Mediwise
  11. BioRad Laboratories
  12. Beckman Coulter
  13. HemoCue AB
  14. Becton Dickinson
  15. T2 Biosystems
  16. Abbott Laboratories

Report Scope and Segmentation

Report ComponentDescription
Market Size (2025)USD 2.8 Billion
Forecast Value (2035)USD 5.9 Billion
CAGR (2026-2035)8.7%
Base Year2025
Historical Period2020-2025
Forecast Period2026-2035
Segments Covered
  • By Product Type:
    • •Portable Analyzers
    • •Handheld Devices
    • •Prefilled Test Kits
  • By Application:
    • •Complete Blood Count
    • •Blood Typing
    • •Coagulation Testing
  • By End Use:
    • •Hospitals
    • •Diagnostic Laboratories
    • •Home Care Settings
  • By Technology:
    • •Microfluidics
    • •Immunoassays
    • •Nucleic Acid Testing
Regional Analysis
  • North America
  • • United States
  • • Canada
  • Europe
  • • Germany
  • • France
  • • United Kingdom
  • • Spain
  • • Italy
  • • Russia
  • • Rest of Europe
  • Asia-Pacific
  • • China
  • • India
  • • Japan
  • • South Korea
  • • New Zealand
  • • Singapore
  • • Vietnam
  • • Indonesia
  • • Rest of Asia-Pacific
  • Latin America
  • • Brazil
  • • Mexico
  • • Rest of Latin America
  • Middle East and Africa
  • • South Africa
  • • Saudi Arabia
  • • UAE
  • • Rest of Middle East and Africa

Table of Contents:

1. Introduction
1.1. Objectives of Research
1.2. Market Definition
1.3. Market Scope
1.4. Research Methodology
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Market Factor Analysis
4.1. Porter's Five Forces Model Analysis
4.1.1. Rivalry among Existing Competitors
4.1.2. Bargaining Power of Buyers
4.1.3. Bargaining Power of Suppliers
4.1.4. Threat of Substitute Products or Services
4.1.5. Threat of New Entrants
4.2. PESTEL Analysis
4.2.1. Political Factors
4.2.2. Economic & Social Factors
4.2.3. Technological Factors
4.2.4. Environmental Factors
4.2.5. Legal Factors
4.3. Supply and Value Chain Assessment
4.4. Regulatory and Policy Environment Review
4.5. Market Investment Attractiveness Index
4.6. Technological Innovation and Advancement Review
4.7. Impact of Geopolitical and Macroeconomic Factors
4.8. Trade Dynamics: Import-Export Assessment (Where Applicable)
5. Global POC Hematology Diagnostic Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
5.1. Market Analysis, Insights and Forecast, 2020-2035, By Product Type
5.1.1. Portable Analyzers
5.1.2. Handheld Devices
5.1.3. Prefilled Test Kits
5.2. Market Analysis, Insights and Forecast, 2020-2035, By Application
5.2.1. Complete Blood Count
5.2.2. Blood Typing
5.2.3. Coagulation Testing
5.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
5.3.1. Hospitals
5.3.2. Diagnostic Laboratories
5.3.3. Home Care Settings
5.4. Market Analysis, Insights and Forecast, 2020-2035, By Technology
5.4.1. Microfluidics
5.4.2. Immunoassays
5.4.3. Nucleic Acid Testing
5.5. Market Analysis, Insights and Forecast, 2020-2035, By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia-Pacific
5.5.4. Latin America
5.5.5. Middle East and Africa
6. North America POC Hematology Diagnostic Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
6.1. Market Analysis, Insights and Forecast, 2020-2035, By Product Type
6.1.1. Portable Analyzers
6.1.2. Handheld Devices
6.1.3. Prefilled Test Kits
6.2. Market Analysis, Insights and Forecast, 2020-2035, By Application
6.2.1. Complete Blood Count
6.2.2. Blood Typing
6.2.3. Coagulation Testing
6.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
6.3.1. Hospitals
6.3.2. Diagnostic Laboratories
6.3.3. Home Care Settings
6.4. Market Analysis, Insights and Forecast, 2020-2035, By Technology
6.4.1. Microfluidics
6.4.2. Immunoassays
6.4.3. Nucleic Acid Testing
6.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
6.5.1. United States
6.5.2. Canada
7. Europe POC Hematology Diagnostic Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
7.1. Market Analysis, Insights and Forecast, 2020-2035, By Product Type
7.1.1. Portable Analyzers
7.1.2. Handheld Devices
7.1.3. Prefilled Test Kits
7.2. Market Analysis, Insights and Forecast, 2020-2035, By Application
7.2.1. Complete Blood Count
7.2.2. Blood Typing
7.2.3. Coagulation Testing
7.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
7.3.1. Hospitals
7.3.2. Diagnostic Laboratories
7.3.3. Home Care Settings
7.4. Market Analysis, Insights and Forecast, 2020-2035, By Technology
7.4.1. Microfluidics
7.4.2. Immunoassays
7.4.3. Nucleic Acid Testing
7.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
7.5.1. Germany
7.5.2. France
7.5.3. United Kingdom
7.5.4. Spain
7.5.5. Italy
7.5.6. Russia
7.5.7. Rest of Europe
8. Asia-Pacific POC Hematology Diagnostic Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
8.1. Market Analysis, Insights and Forecast, 2020-2035, By Product Type
8.1.1. Portable Analyzers
8.1.2. Handheld Devices
8.1.3. Prefilled Test Kits
8.2. Market Analysis, Insights and Forecast, 2020-2035, By Application
8.2.1. Complete Blood Count
8.2.2. Blood Typing
8.2.3. Coagulation Testing
8.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
8.3.1. Hospitals
8.3.2. Diagnostic Laboratories
8.3.3. Home Care Settings
8.4. Market Analysis, Insights and Forecast, 2020-2035, By Technology
8.4.1. Microfluidics
8.4.2. Immunoassays
8.4.3. Nucleic Acid Testing
8.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. South Korea
8.5.5. New Zealand
8.5.6. Singapore
8.5.7. Vietnam
8.5.8. Indonesia
8.5.9. Rest of Asia-Pacific
9. Latin America POC Hematology Diagnostic Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
9.1. Market Analysis, Insights and Forecast, 2020-2035, By Product Type
9.1.1. Portable Analyzers
9.1.2. Handheld Devices
9.1.3. Prefilled Test Kits
9.2. Market Analysis, Insights and Forecast, 2020-2035, By Application
9.2.1. Complete Blood Count
9.2.2. Blood Typing
9.2.3. Coagulation Testing
9.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
9.3.1. Hospitals
9.3.2. Diagnostic Laboratories
9.3.3. Home Care Settings
9.4. Market Analysis, Insights and Forecast, 2020-2035, By Technology
9.4.1. Microfluidics
9.4.2. Immunoassays
9.4.3. Nucleic Acid Testing
9.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East and Africa POC Hematology Diagnostic Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
10.1. Market Analysis, Insights and Forecast, 2020-2035, By Product Type
10.1.1. Portable Analyzers
10.1.2. Handheld Devices
10.1.3. Prefilled Test Kits
10.2. Market Analysis, Insights and Forecast, 2020-2035, By Application
10.2.1. Complete Blood Count
10.2.2. Blood Typing
10.2.3. Coagulation Testing
10.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
10.3.1. Hospitals
10.3.2. Diagnostic Laboratories
10.3.3. Home Care Settings
10.4. Market Analysis, Insights and Forecast, 2020-2035, By Technology
10.4.1. Microfluidics
10.4.2. Immunoassays
10.4.3. Nucleic Acid Testing
10.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. UAE
10.5.4. Rest of Middle East and Africa
11. Competitive Analysis and Company Profiles
11.1. Market Share of Key Players
11.1.1. Global Company Market Share
11.1.2. Regional/Sub-Regional Company Market Share
11.2. Company Profiles
11.2.1. A. Menarini Diagnostics
11.2.1.1. Business Overview
11.2.1.2. Products Offering
11.2.1.3. Financial Insights (Based on Availability)
11.2.1.4. Company Market Share Analysis
11.2.1.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.1.6. Strategy
11.2.1.7. SWOT Analysis
11.2.2. PathogenDx
11.2.2.1. Business Overview
11.2.2.2. Products Offering
11.2.2.3. Financial Insights (Based on Availability)
11.2.2.4. Company Market Share Analysis
11.2.2.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.2.6. Strategy
11.2.2.7. SWOT Analysis
11.2.3. Siemens Healthineers
11.2.3.1. Business Overview
11.2.3.2. Products Offering
11.2.3.3. Financial Insights (Based on Availability)
11.2.3.4. Company Market Share Analysis
11.2.3.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.3.6. Strategy
11.2.3.7. SWOT Analysis
11.2.4. Sysmex Corporation
11.2.4.1. Business Overview
11.2.4.2. Products Offering
11.2.4.3. Financial Insights (Based on Availability)
11.2.4.4. Company Market Share Analysis
11.2.4.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.4.6. Strategy
11.2.4.7. SWOT Analysis
11.2.5. Ortho Clinical Diagnostics
11.2.5.1. Business Overview
11.2.5.2. Products Offering
11.2.5.3. Financial Insights (Based on Availability)
11.2.5.4. Company Market Share Analysis
11.2.5.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.5.6. Strategy
11.2.5.7. SWOT Analysis
11.2.6. Acon Laboratories
11.2.6.1. Business Overview
11.2.6.2. Products Offering
11.2.6.3. Financial Insights (Based on Availability)
11.2.6.4. Company Market Share Analysis
11.2.6.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.6.6. Strategy
11.2.6.7. SWOT Analysis
11.2.7. Greiner BioOne
11.2.7.1. Business Overview
11.2.7.2. Products Offering
11.2.7.3. Financial Insights (Based on Availability)
11.2.7.4. Company Market Share Analysis
11.2.7.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.7.6. Strategy
11.2.7.7. SWOT Analysis
11.2.8. Roche Holding
11.2.8.1. Business Overview
11.2.8.2. Products Offering
11.2.8.3. Financial Insights (Based on Availability)
11.2.8.4. Company Market Share Analysis
11.2.8.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.8.6. Strategy
11.2.8.7. SWOT Analysis
11.2.9. Hematologic Technologies
11.2.9.1. Business Overview
11.2.9.2. Products Offering
11.2.9.3. Financial Insights (Based on Availability)
11.2.9.4. Company Market Share Analysis
11.2.9.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.9.6. Strategy
11.2.9.7. SWOT Analysis
11.2.10. Mediwise
11.2.10.1. Business Overview
11.2.10.2. Products Offering
11.2.10.3. Financial Insights (Based on Availability)
11.2.10.4. Company Market Share Analysis
11.2.10.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.10.6. Strategy
11.2.10.7. SWOT Analysis
11.2.11. BioRad Laboratories
11.2.11.1. Business Overview
11.2.11.2. Products Offering
11.2.11.3. Financial Insights (Based on Availability)
11.2.11.4. Company Market Share Analysis
11.2.11.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.11.6. Strategy
11.2.11.7. SWOT Analysis
11.2.12. Beckman Coulter
11.2.12.1. Business Overview
11.2.12.2. Products Offering
11.2.12.3. Financial Insights (Based on Availability)
11.2.12.4. Company Market Share Analysis
11.2.12.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.12.6. Strategy
11.2.12.7. SWOT Analysis
11.2.13. HemoCue AB
11.2.13.1. Business Overview
11.2.13.2. Products Offering
11.2.13.3. Financial Insights (Based on Availability)
11.2.13.4. Company Market Share Analysis
11.2.13.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.13.6. Strategy
11.2.13.7. SWOT Analysis
11.2.14. Becton Dickinson
11.2.14.1. Business Overview
11.2.14.2. Products Offering
11.2.14.3. Financial Insights (Based on Availability)
11.2.14.4. Company Market Share Analysis
11.2.14.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.14.6. Strategy
11.2.14.7. SWOT Analysis
11.2.15. T2 Biosystems
11.2.15.1. Business Overview
11.2.15.2. Products Offering
11.2.15.3. Financial Insights (Based on Availability)
11.2.15.4. Company Market Share Analysis
11.2.15.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.15.6. Strategy
11.2.15.7. SWOT Analysis
11.2.16. Abbott Laboratories
11.2.16.1. Business Overview
11.2.16.2. Products Offering
11.2.16.3. Financial Insights (Based on Availability)
11.2.16.4. Company Market Share Analysis
11.2.16.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.16.6. Strategy
11.2.16.7. SWOT Analysis

List of Figures

List of Tables

Table 1: Global POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Product Type, 2020-2035

Table 2: Global POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 3: Global POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 4: Global POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Technology, 2020-2035

Table 5: Global POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Region, 2020-2035

Table 6: North America POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Product Type, 2020-2035

Table 7: North America POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 8: North America POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 9: North America POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Technology, 2020-2035

Table 10: North America POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Country, 2020-2035

Table 11: Europe POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Product Type, 2020-2035

Table 12: Europe POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 13: Europe POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 14: Europe POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Technology, 2020-2035

Table 15: Europe POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 16: Asia Pacific POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Product Type, 2020-2035

Table 17: Asia Pacific POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 18: Asia Pacific POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 19: Asia Pacific POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Technology, 2020-2035

Table 20: Asia Pacific POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 21: Latin America POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Product Type, 2020-2035

Table 22: Latin America POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 23: Latin America POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 24: Latin America POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Technology, 2020-2035

Table 25: Latin America POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 26: Middle East & Africa POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Product Type, 2020-2035

Table 27: Middle East & Africa POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 28: Middle East & Africa POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 29: Middle East & Africa POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Technology, 2020-2035

Table 30: Middle East & Africa POC Hematology Diagnostic Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Frequently Asked Questions

Industry

Healthcare Market Research

Explore comprehensive market research reports covering all aspects of the Healthcare industry, including market size, growth trends, competitive landscape, and strategic insights.

View Industry Page
;